SCHEMBL11543795

SCHEMBL11543795

CC(=O)CCCc1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
HSD17B10 Q99714 1/20 0.50
HPGD P15428 2/20 0.49
ALDH1A1 P00352 1/20 0.48
FFAR1 O14842 1/20 0.47
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
NAAA Q02083 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HDAC1 Q13547 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11536859 0.94 NAAA (0.50) LMNAHSD17B10HPGDALDH1A1FFAR1
SCHEMBL11638377 0.92 FAAH (0.50) LMNAHPGDALDH1A1FFAR1NAAA
SCHEMBL409318 0.88 ALDH1A1 (0.63) LMNAHPGDALDH1A1FFAR1SLC5A1
SCHEMBL10327290 0.84 LTA4H (0.46) LMNAALDH1A1FFAR1NAAA
SCHEMBL23003726 0.83 LMNA (0.56) LMNAHPGDFFAR1SLC5A1SLC5A2
SCHEMBL28799311 0.83 LMNA (0.47) LMNAHSD17B10HPGDTAAR1
SCHEMBL658360 0.82 LMNA (0.54) LMNAHPGDFFAR1SLC5A1SLC5A2
SCHEMBL655425 0.82 SMN1; SMN2 (0.67) LMNAHSD17B10ALDH1A1FFAR1HDAC3
SCHEMBL105767 0.82 HSD17B10 (0.52) HSD17B10ALDH1A1FFAR1SLC5A1SLC5A2
SCHEMBL19907263 0.82 LMNA (0.46) LMNAHSD17B10HPGDTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 US disclosed
WO-2019178063-A1 PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF HAWAII BIOTECH, INC. (US) 2019-09-19 WO disclosed
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2019-06-13 US disclosed
US-4160036-A ADRENERGIC STIMULANTS ALLEN & HANBURYS LIMITED (GB) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787484-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 LMNA 136/4885HSD17B10 315/4885HPGD 2382/4885
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 LMNA 136/4885HSD17B10 315/4885HPGD 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.